Assessing the Risk of Epstein-Barr Virus-Related Lymphoproliferative Disorders Before Administration of Visilizumab

Gastroenterology

Volumn 134, Issue 3, 2008, Pages 895-896

  Guthery, Stephen L ^a   Gross, Thomas G ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Section of Hematology/Oncology/Blood and Marrow Transplant   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; VISILIZUMAB;

AGE; BIOLOGICAL ACTIVITY; CANCER RISK; DRUG SAFETY; EPSTEIN BARR VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LATENT VIRUS INFECTION; LETTER; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS;

EID: 40049112283     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.01.023     Document Type: Letter

References (3)

1. S. Plevy B. Salzberg G. Van Assche A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis Gastroenterology 133 2007 1414 1422
2. S.L. Guthery J.E. Heubi J.C. Bucuvalas Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment Transplantation 75 2003 987 993
3. A.J. Swerdlow C.D. Higgins B.J. Hunt Risk of lymphoid neoplasia after cardiothoracic transplantation A cohort study of the relation to Epstein-Barr virus Transplantation 69 2000 897 904